MediciNova, Inc. (NASDAQ:MNOV) Given Consensus Rating of "Moderate Buy" by AnalystsMarket Beat·Jul 26 at 03:14 AMMNOV+3.88%STT+3.85%
MediciNova: Differentiated NAFLD/MASH Profile and Complementary APOC3 Positioning Support Unchanged $6 Target and Buy RatingTip Ranks·Jul 23 at 04:25 PMMNOV+3.88%
MediciNova says SEANOBI-ALS expanded-access study of MN-166 reaches 200-patient enrollment targetPUBT·Jul 15 at 07:03 AMMNOV+3.88%4875
MediciNova Announces Patient Enrollment Milestone Achieved in SEANOBI Study Expanded-Access-Program Evaluating MN‑166 (ibudilast) in ALS patientsUnusual Whales·Jul 15 at 07:02 AM4875MNOV+3.88%
Analyst Reiterates Buy on MediciNova as Advancing Pipeline and Upcoming ALS Catalysts Support Unchanged $6 Price TargetTip Ranks·Jul 1 at 02:35 PMMNOV+3.88%
MediciNova says US patent office allows ibudilast–anti-PD-1 combo claims for glioblastoma treatmentPUBT·Jun 30 at 07:04 AMMNOV+3.88%
MediciNova stockholders reject proposal to boost authorized common shares to 247 millionPUBT·Jun 24 at 03:40 PMMNOV+3.88%
MediciNova Receives Notice of Allowance for New Patent Covering Use of MN-166 in Combination with Anti-PD-1 Immune Checkpoint Inhibitor for Glioblastoma TreatmentUnusual Whales·Jun 8 at 07:02 AMMNOV+3.88%4875
MediciNova Concludes Phase 2 For MN-001 In Treating Diabetic Non-Alcoholic Fatty Liver Diseasenasdaq·May 27 at 04:00 AMMNOV+3.88%
MediciNova Announces Completion of Last Patient Last Visit in the MN-001-NATG-202 Clinical Trial of MN-001 (Tipelukast) | MNOV Stock NewsStockTitan·May 26 at 10:00 AM4875MNOV+3.88%
<![CDATA[Modern Communication Between FDA, Biotech, and Investors: Q&A with David Crean]]>Pharmexec·May 22 at 05:00 AM4875MNOV+3.88%
Medicinova: Buy Rating Reiterated as Pipeline Advances and Cash Runway Extends, $6 Price Target MaintainedTip Ranks·May 21 at 10:55 AMMNOV+3.88%
New Peer‑Reviewed Study Reveals Actionable Immune–Microenvironment Target in Brain Metastasis; Medicinova Advances Clinical TranslationUnusual Whales·Apr 27 at 06:01 PMMNOV+3.88%
